- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment
- Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills
- New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics
The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization (CRO) was named Champion in multiple categories of the 2020 CRO Leadership Awards, and was the only CRO named as Champion in the Quality category.
25 June 2020, Oxfordshire, UK - Scientists from UK-headquartered AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyze the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2.
Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the
American Association for Cancer Research (AACR). The data concerns the company’s proprietary
immunomodulatory agent, MDX-124, which has been shown to reduce cancer cell growth by up to 76%
in a broad range of cancer cell lines.
NORWICH, UK - 17 June 2020: Leaf Expression Systems (Leaf), a contract development and manufacturing organisation based in Norwich, UK, has announced today that it has developed a recombinant SARS-CoV-2 N-protein (antigen) to aid research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) pandemic.